{ "items" : [
    { "id" : "http://webisa.webdatacommons.org/204501466"
      "properties" : {
        "http://www.w3.org/1999/02/22-rdf-syntax-ns#type" : [ "http://www.w3.org/ns/prov#Entity" ] ,
        "http://www.w3.org/ns/prov#value" : [ "The company has been hit with some specific problems in the last few years, particularly the delay of its type 2 diabetes med, Galvus (which received an approvable letter in February), and the withdrawal of Zelnorm, for safety concerns." ] ,
        "http://www.w3.org/ns/prov#wasQuotedFrom" : [ "pharmexec.com" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/223335523"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/204501466"] } } }
